Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss
Executive Summary
Schizophrenia drug licensed from Takeda missed Phase II endpoint for negative symptoms, but hits secondary cognition endpoints. Neurocrine plans to further study compound for cognitive benefits.
You may also be interested in...
Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win
The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.
Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie
Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.
Stock Watch: Should A Biotech’s First Product Be Out-Licensed Or Self-Marketed?
The licensing or self-commercialization decision can be important for the success of a biotech company, but do other more fundamental factors concerning the drug dictate a company’s success?